Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Regenerative Stenting for Osteoporotic Vertebral Fracture Repair

Project description

A new treatment for osteoporotic vertebral fracture

Osteoporotic vertebral fractures (OVFs) represent a medical challenge, frequently complicating osteoporosis. Current treatments rely on injecting cement into vertebrae to stabilise the spine and alleviate pain, offering palliative relief without addressing the underlying issue. However, no reparative treatment exists to address the structural deterioration of bone in OVFs. Biomaterial-based approaches, though promising, face hurdles, hindering their effectiveness in providing both mechanical support and therapeutic benefits. In this context, the ERC-funded RESTORE project harnesses advanced manufacturing and 3D-printing to engineer a dual-component biomaterial platform. Comprising a biodegradable stent and a thermo-responsive hydrogel, this innovation is tailored to regenerate and repair osteoporotic vertebral bone. Additionally, the hydrogel will deliver antioxidants to combat oxidative stress and promote bone regeneration.

Objective

Osteoporotic vertebral fractures (OVFs) are the most common complication of osteoporosis. Current treatment involves conventional procedures that inject cement into the vertebrae to stabilise the spine and relieve pain. No reparative treatment exists. Biomaterial-based treatments have had very limited success due to a number of complex challenges, such as providing dual therapeutic and mechanical functionalities to meet clinical requirements. Building on a wealth of experience in the area of materials processes, we propose the solution. RESTORE will initially overcome the problems with traditional biomaterials approaches by utilising recent advances in the area of advanced manufacturing and 3D-printing to engineer a dual component biomaterial platform, comprising of a 3D-printed biodegradable stent and a thermoresponsive hydrogel, with mechanical properties and bioactive composition tailored to regenerate and repair osteoporotic vertebral bone. Following this, and consolidating the research in the applicant’s lab on biomaterial-mediated delivery of therapeutics to enhance bone formation and inhibit resorption, the hydrogel component will be functionalised for the controlled delivery of antioxidant lanthanides, to combat increased oxidative stress in the osteoporotic bone microenvironment, and modulate impaired bone remodelling to drive bone regeneration and facilitate repair. The RESTORE technology has potential for use in a patient specific personalized medicine format as the 3D-printing process utilised allows for the stents to be tailored to the patient’s individual vertebra. The hydrogel’s therapeutic load can also be adjusted and offers a potential minimally invasive prophylactic treatment for adjacent diseased vertebrae that do not yet require stenting - a first-of-its-kind prevention strategy for OVFs. The proposed RESTORE platform is thus a paradigm shifting disruptive technology that will revolutionise the way damaged osteoporotic vertebrae are treated.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-COG

See all projects funded under this call

Host institution

ROYAL COLLEGE OF SURGEONS IN IRELAND
Net EU contribution
€ 2 039 473,00
Address
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Ireland
Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 039 473,00

Beneficiaries (1)